VIVUS Announces Scientific Presentations

VIVUS Announces Scientific Presentations

MOUNTAIN VIEW, Calif., June 3, 2013 (GLOBE NEWSWIRE) -- VIVUS,Inc.
(Nasdaq:VVUS), a biopharmaceutical company commercializing and developing
innovative, next-generation therapies to address unmet needs in obesity and
sexual health, today announced the following scientific presentations:

Conference

SLEEP 2013: 27^th Annual Meeting of the Associated Professional Sleep
Societies (APSS)
June 1-5, 2013
Baltimore Convention Center, Baltimore, Maryland

Date/Time

Poster Presentation Date: Tuesday, June 4^th, 2013 from 4:00-6:00 PM
Session Location: Exhibit Hall E, 100 level, Baltimore Convention Center
Poster Number: 205
Abstract Number: 0867

Presentation Title

The Effects of Once-Daily Phentermine 15 mg and Topiramate Extended-Release 92
mg on Cardiometabolic Endpoints in Obese Patients With Obstructive Sleep Apnea

Authors: David H. Winslow, MD^a; Charles H. Bowden, MD^b; Karen DiDonato, RN,
MSN^b; Pamela A. McCullough, PhD^a

Affiliations: ^aKentucky Research Group, Louisville, KY;^bVIVUS, Inc.,
Mountain View, CA

Conference

81^st Annual Scientific Meeting of the European Atherosclerosis Society
Congress (EAS)
June 2-5, 2013
LYON Congress Center, Lyon, France

Date/Time

Poster Presentation Date: Monday, June 3^rd and Tuesday, June 4^th, 2013 from
12:30-15:00 both days; Session Location: Center of the Exhibition area, Lyon
Congress Centre

Poster Session: RISK FACTORS, EPIDEMIOLOGY, PREVENTION, AND TREATMENT OF
CARDIOVASCULAR DISEASES, under topic "Obesity and fat distribution"

Poster Number: 430

Presentation Title

Weight Loss–Induced Improvements in Lipids in Overweight/Obese Subjects
Treated With Phentermine and Topiramate Extended-Release

Authors: Hermann Toplak, MD^a; Samuel Klein, MD^b; Wesley W. Day, PhD^c

Affiliations: ^aMedical University of Graz, Graz, Austria; ^bWashington
University School of Medicine, St Louis, Missouri, USA; ^cVIVUS, Inc.,
Mountain View, California, USA

About Qsymia

Qsymia^® (phentermine and topiramate extended-release) capsules CIV is
approved in the U.S. and is indicated as an adjunct to a reduced-calorie diet
and increased physical activity for chronic weight management in adults with
an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or
greater (overweight) in the presence of at least one weight-related medical
condition such as high blood pressure, type 2 diabetes, or high cholesterol.

The effect of Qsymia on cardiovascular morbidity and mortality has not been
established. The safety and effectiveness of Qsymia in combination with other
products intended for weight loss, including prescription and over-the-counter
drugs, and herbal preparations, have not been established.

Important Safety Information

Qsymia^® (phentermine and topiramate extended-release) capsules CIV is
contraindicated in pregnancy; in patients with glaucoma; in hyperthyroidism;
in patients receiving treatment or within 14 days following treatment with
monoamine oxidase inhibitors (MAOIs); or in patients with hypersensitivity to
sympathomimetic amines, topiramate, or any of the inactive ingredients in
Qsymia.

Qsymia can cause fetal harm. Females of reproductive potential should have a
negative pregnancy test before treatment and monthly thereafter and use
effective contraception consistently during Qsymia therapy. If a patient
becomes pregnant while taking Qsymia, treatment should be discontinued
immediately, and the patient should be informed of the potential hazard to the
fetus.

The most commonly observed side effects in controlled clinical studies, 5% or
greater and at least 1.5 times placebo, include paraesthesia, dizziness,
dysgeusia, insomnia, constipation, and dry mouth.

About VIVUS

VIVUS is a biopharmaceutical company commercializing and developing
innovative, next-generation therapies to address unmet needs in obesity and
sexual health. For more information about the company, please visit
www.vivus.com.

Certain statements in this press release are forward-looking within the
meaning of the Private Securities Litigation Reform Act of 1995. These
statements may be identified by the use of forward-looking words such as
"anticipate," "believe," "forecast," "estimate," "expect," "intend," "likely,"
"may," "plan," "potential," "predict," "opportunity" and "should," among
others. There are a number of factors that could cause actual events to differ
materially from those indicated by such forward-looking statements. VIVUS does
not undertake an obligation to update or revise any forward-looking
statements. Investors should read the risk factors set forth in VIVUS's Form
10-K for the year ending December 31, 2012, as amended by the Form 10-K/A
filed on April 30, 2013, and periodic reports filed with the Securities and
Exchange Commission.

CONTACT: VIVUS, Inc.
         Dana B. Shinbaum
         Corporate Development
         & Investor Relations
         shinbaum@vivus.com
        
         Investor Relations:
         The Trout Group
         Brian Korb
         bkorb@troutgroup.com
         646-378-2923
 
Press spacebar to pause and continue. Press esc to stop.